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T he knowledge that sera from pregnant women contain pregnancy-specific hormones is not new. Ascheim and 
Zondek discovered chorionic gonadotropin 
in 1927.1 However, it was not until 1962 that 
a second hormone, namely, human p la­
cental lactogen (hPL), was isolated.2 Both of 
these substances are glycoproteins produced 
by the syncytiotrophoblast and released 
predominantly into the maternal circula­
tion. Human placental lactogen in particu­
lar has been widely employed for clinical 
fetoplacental assessment.3
Although it has long been suspected that 
other hormones are present in the sera of 
pregnant women, it has only been within 
the past decade that improved laboratory 
techniques plus increased interest have re­
sulted in the isolation of numerous other 
pregnancy-associated and/or trophoblast- 
specific hormones. The purpose of this
article will be to review the role of hPL and 
the newer hormones as indicators of fetal 
well-being.
Human Placental Lactogen
As mentioned, the isolation and purifi­
cation of hPL was accomplished in 1962 by 
Josimovich and MacLaren.2 Hum an p la­
cental lactogen is a single-chain protein of 
190 amino acids with two interchain di­
sulfide bonds and a molecular weight of 
21-23 K. The chemical characterization and 
primary sequencing as described by Sher­
wood and Handwerger4 have confirmed an 
84% homology between the amino acid 
sequence of hPL and hum an growth hor­
mone (hGH). More recently, Shine et al. and 
Seeburg et al.5'6 were able to reconstruct the 
complementary DNA nucleotide sequence
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TABLE 1. Alternative N om enclature of Preg­
nancy H orm ones*
I. Schwangerschaftsspecifiche betai-glycoprotein 
(Sp i )
Pregnancy-specific betai-glycoprotein (PSBG) 
Pregnancy-associated plasma protein C 
(PAPP-C)
Trophoblast-specific betai-globulin (TSG)
II. Human placental lactogen (hPL)
Human chorionic somatomammotropin (hCS) 
Pregnancy-associated plasma protein D 
(PAPP-D)
III. Pregnancy-associated alpha2-glycoprotein 
(a2-PAG)
Pregnancy zone protein (PZP) 
Pregnancy-associated alpha2-globulin 
Alpha2-pregnoglobulin
•Other hormones are commonly referred to by a 
single name.
for hPL and reconfirmed its extensive ho­
mology with hGH. As might be anticipated 
from its structural homologies, hPL re­
sembles both prolactin and hGH in its 
bioactivity. In both traditional bioassays 
and in receptor-binding studies, hPL is 
cross-reactive with both hGH and prolactin. 
Human placental lactogen shows a high  
degree of binding with lactogenic receptors, 
and its activity at these receptors is equal to 
that of hGH. A weaker cross-reactivity is 
seen with lymphocyte receptors for hGH  
(0.03% specific binding). Human prolactin, 
by contrast, showed no activity in this 
system.7 Specific hPL receptors have not 
been isolated in humans, and the biologic 
activity of hPL is presumed to be mediated 
through prolactin and hGH receptors.
Human placental lactogen is synthesized 
through a precursor called pro-hPL, which 
is larger by some 25 amino acids than the 
mature hormone. The precursor is cleaved 
on the endoplasmic membrane prior to 
secretion.8'9 Synthesized by the syncytio- 
trophoblast, hPL can be isolated from ma­
ternal and fetal serum, maternal urine, and 
amniodc fluid. Both maternal and neonatal 
serum levels drop rapidly follow ing delivery 
but maternal levels remain unchanged if 
selective fetectomy is performed and the 
placenta left in situ. A serum half-life of 30 
minutes has been derived by Samaan.10
Human placental lactogen secretion at term 
may reach 3 g/24 hr in normal pregnancies, 
and it is a major protein synthetic product of 
the human placenta near term.
Human placental lactogen secretion is 
largely autonomous. The serum levels show 
no circadian rhythm and no consistent 
variation with changes in maternal posture, 
activity level, smoking, the onset of labor, or 
brief periods of hypoglycem ia.11-13 T hehPL  
concentration in maternal serum is some 300 
times greater than the level in umbilical 
venous blood. HPL enters amniotic fluid by 
simple diffusion14; and its levels in amniotic 
fluid, are parallel to, but much lower than, 
maternal levels.15 The function of the small 
quantities of hPL found in amniotic fluid 
and fetal serum is unknown.
Production of hPL during gestation can 
first be detected by radioimmunoassay at 
20-40 days after implantation and shows a 
gradual rise until 37 weeks’ gestation. Be­
yond this time a slight but progressive 
decline occurs, and by 42 weeks’ gestation a 
significant decrease can be demonstrated.16
The rise in maternal serum hPL levels 
parallels the increase in placental volume 
during pregnancy. As might be expected, 
clinical conditions resulting in larger pla­
cental mass, such as m ultiple pregnancy, 
erythroblastosis, and poorly controlled ma­
ternal diabetes mellitus, are associated with 
higher maternal serum hPL values.
The action of hPL on human tissue and 
its proposed physiologic role in pregnancy 
have been extensively investigated. W hile 
hPL does have growth hormone-like acti­
vities, these activities are weak. Doses 200 
times those of hGH are necessary to show  
equivalent growth stim ulation.17 Human 
placental lactogen can also stimulate pro­
duction of somatomedins in both pregnant 
and nonpregnant subjects. By the action of 
maternal somatomedins at specific placen­
tal receptors, it has been suggested, hPL  
may contribute to the regulation of substrate 
availability to the growing fetus.18
The lactogenic activity of hPL has been 
documented in animal m odels.19 However,
675
HPL AND FETA L WELL-BEING
current evidence from human studies does 
not support a role for hPL in preparation for 
human lactation. In addition, hPL is not 
luteotropic in human studies.20 An im ­
munosuppressive effect has been demon­
strated for hPL21,22
Human placental lactogen also has effects 
on fat metabolism. Administration of hPL  
to nonpregnant hypopituitary dwarfs in 
concentrations adequate to achieve blood 
levels seen in late pregnancy increases serum 
free fatty acids and glycerol.23 It also stimu­
lates lipolysis in adipose tissue in both 
gravid and nongravid wom en.24 It has been 
suggested that this increased lipolytic activ­
ity is due to the action of a hormone- 
sensitive lipase.25
The effect of hPL on carbohydrate metab­
olism has also been extensively studied. 
With hPL infusions, impaired glucose tol­
erance in nonpregnant women has been 
demonstrated despite augmented insulin  
responses.26 In hypophysectomized non­
pregnant diabetics, hPL influsion increased 
fasting glucose and urinary glucose excre­
tion and decrease glucose tolerance.27 H u­
man placental lactogen is postulated to con­
tribute to this relative insulin resistance and 
glucose-sparing as a result of its actions on 
adipose cells, causing increased intracellular 
free fatty acid levels, which then block peri­
pheral uptake and utilization of glucose. 
Such increases in free fatty acids can inhibit 
the enzymatic reactions necessary for glyco­
lysis. As previously stated, accelerated lipo­
lysis also increases serum free fatty acid and 
triglyceride levels, allowing the transfer of 
triglycerides and free fatty acids to the liver 
for gluconeogenesis, further facilitating 
glucose availability.
The presence of high hPL levels in 
maternal serum and its described physio­
logic effects on fatty acid and carbohydrate 
metabolism have led to speculation that 
hPL functions as a major physiologic 
regulator of intermediary metabolism in late 
pregnancy. Through its glucose-sparing 
and free-fatty-acid-mobilizing acidvites, 
hPL helps assure a constant supply of
glucose to the developing fetus. Although 
such statements imply a definite require­
ment for hPL during normal pregnancy, it 
is worth noting that it is apparently possible 
to complete normal pregnancies in the ab­
sence of hPL secretion,28 31 as an increasing 
number of case reports document. No sex 
linkage has been confirmed,28 and no asso­
ciated placental or maternal abnormalities 
have been found with hPL deficiency.
As previously mentioned, the major de­
terminant of maternal serum hPL con­
centration is the volume of functional 
syncytiotrophoblast. Human placental 
lactogen has, therefore, been evaluated 
extensively in an attempt to monitor pla­
cental function and thereby assess fetal w ell­
being. Numerous studies have evaluated 
hPL values in early complications of preg­
nancy. In patients with first-trimester 
threatened abortion, low maternal serum 
hPL values have correlated with an in ­
creased risk of subsequent miscarriage.32-34 
However, such correlations are far from per­
fect, and it seems generally agreed that thera­
peutic intervention of nonintervention 
should not be based on hPL values alone.
Human placental lactogen has been stud­
ied in patients with molar pregnancy and 
trophoblastic tumors. In general, hPL  
values are substantially lower than would be 
expected in normal pregnancies of similar 
duration.35 Human chorionic gonadotropin 
levels are considered to be of more value in 
the monitoring of such patients. Goldstein 
has also shown that hPL levels are lower 
when the trophoblastic tissue appears m alig­
nant.36 Human placental lactogen has also 
been isolated from the sera of patients with 
nontrophoblastic tumors,37 including lung  
and liver tumors, lymphoma, and pheo- 
chromocytoma.
As mentioned, normative studies have 
demonstrated a progressive rise in maternal 
serum hPL values until 37 weeks’ gestation, 
after which time levels remain constant or 
decline slightly.16,38-41 Mean values near 
term are in the range of 5.4-7.0^tg/ml, with 
those values below 4jig/m l generally be­
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lieved to represent a small placenta and, 
therefore, an increased probability of feto­
placental compromise. Values of less than 4 
Mg/ml beyond 30 weeks’ gestation have been 
designated as being within the “fetal danger” 
zone,42 with consistently low values being as 
ominous as values that decrease from the 
normal range. Spellacy has reported that the 
risk to the fetus progressively increases with 
progressive decreases in maternal serum 
hPL values.43
Maternal serum hPL has been advocated 
as a screening procedure for all pregnant 
patients.44"47 However, other studies,48"52 the 
majority of which have been in recent years, 
have questioned the efficacy of this ap­
proach and have suggested that hPL deter­
minations be reserved for specific clinically 
identifiable high-risk pregnancies.
The incidence and degree of fetoplacental 
macrosomia with maternal diabetes m el­
litus has progressively diminished as closer 
attention has been directed toward careful 
blood glucose control. In spite of this, the 
placentas in diabetic pregnancies are of­
ten large, and most investigators report nor­
mal to high hPL levels in diabetic preg­
nancies.41,53"56 In spite of suggestions that 
the fetal danger zone be revised upward, hPL  
determinations have been of limited value in 
the management of diabetic pregnancy, be­
cause many diabetic stillbirths occur as 
acute events unrelated to chronic and/or 
progressive placental insufficiency.
The incidence of pregnancies com pli­
cated anti-D isoimmunization has dim in­
ished because of passive immunization  
techniques as well as improved blood cross­
matching procedures. However, a persistent 
number of isoimmunized patients are still 
encountered. Because significantly involved 
gestations are associated with large pla­
centas, hPL values might be expected to be in 
or above the normal range. Several reviews 
have found this to be the case.41,54,57"59 Like 
those related to diabetes, isoimmunization- 
related stillbirths often occur as a result of 
acute or subacute fetal disease unrelated to 
chronic and/or progressive placental in­
sufficiency. Human placental lactogen is 
thus of little value in the monitoring of preg­
nancies complicated by isoimmunization.
Multiple gestation remains a significant 
contributor to perinatal wastage, partially 
because of an increase risk of preeclampsia 
and premature delivery and partially be­
cause of a persistent clinical inability to 
diagnose the condition early enough in 
pregnancy to allow early monitoring or 
therapy for complications of pregnancy. 
Because of the increased syncytiotropho- 
blast mass associated with m ultiple ges­
tation, maternal serum hPL concentrations 
might be expected to be elevated in all three 
trimesters. This has been documented by 
several investigators.60-62 Maternal serum 
hPL screening, with follow-up ultrasound 
examination of elevated values, has been 
reported and has both improved the inci­
dence of diagnosis and permitted the diag­
nosis to be made earlier in pregnancy.63
In the past two decades the importance of 
adequate fetal growth for duration of 
gestation has been recognized. Inadequate 
fetal growth for duration of gestation, 
commonly called intrauterine growth retar­
dation (IUGR) is a clinically important 
corollary. IUGR may be the result of any 
combination of maternal, fetal, or placental 
diseases and has repetitively been shown to 
be associated with increased perinatal mor­
bidity and mortality.64,65 Most attempts to 
detect IUGR by clinical parameters alone 
have been disappointing, identifying only 
about 30% of those infants in the lowest 10th 
percentile of weight for gestational age.66 
Because IUGR is frequently associated with 
a reduction in functional placental tissue, 
maternal serum hPL values have been 
extensively evaluated in an attempt to 
improve the antenatal detection and treat­
ment of IUGR. The results are inconclusive; 
some studies have been extremely opti­
mistic,67,68 others have been pessimistic,69 
and the majority report low maternal serum 
hPL values in 32%70 to 60%41 of IUGR  
pregnancies. The predictive ability of hPL  
alone thus is not good.
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Several authors have recommended that 
IUGR be suspected in all near-term preg­
nancies in which the maternal serum hPL  
value is less than 5 /ug/ml.41,71 Certainly any 
patient thus identified should be carefully 
monitored with several accepted means of 
assessing fetal well-being, both during the 
remaining antepartum period as well as 
during labor. However, Hobbins and Berko- 
witz72 have reported that when hPL is used 
as the sole identifier of patients at risk for 
IUGR, approximately one-third of actual 
IUGR fetuses would not have the benefit of 
additional fetal surveillance. Since hPL is a 
placental hormone (and not all cases of 
IUGR are related to placental insufficiency), 
it is not unexpected that some cases of IUGR  
are associated with normal hPL values.
It has long been recognized that hyper­
tension in pregnancy is associated with 
small placentas, and evidence exists that 
suggests that the observed lowering of 
maternal serum hPL values associated with  
hypertension is proportional to the dim i­
nution of placental villous surface area.73
In a study of pregnancies complicated by 
hypertension, Kelly and associates74 found 
that hPL most accurately predicted fetal 
compromise when associated with IUGR. Of 
perhaps greater significance, only 50% of the 
adverse outcomes (neonatal asphyxia, fetal 
distress, or IUGR) were predicted by low  
hPL values. Morrison and associates75 also 
found that hPL values were acceptably 
sensitive only in those hypertensive preg­
nancies associated with growth-retarded 
fetuses.
In preeclampsia, hPL values also tend to 
be reduced, generally being lowest in m ulti­
gravidas with severe hypertension.
From these and other reported series, it 
appears that hPL levels are often subnormal 
in hypertensive pregnancies. Low values are 
frequently associated with fetal or neonatal 
distress, but this is by no means always the 
case. Conversely, the presence of normal 
hPL values should not be interpreted as an 
assurance that complications will not occur. 
Several studies76,77 suggest that hPL may
provide some additional diagnostic speci­
ficity when combined with other parameters 
of fetoplacental well-being.
Although many postdate obstetric pa­
tients are subjected to varying fetoplacental 
surveillance protocols, a significant number 
of them will have no evidence of IUGR or 
fetal compromise and will deliver healthy 
infants. A frequent explanation can be 
found in the difficulties associated with the 
correct assessment of the duration of ges­
tation, especially in women with irregular 
menses, who become pregnant shortly after 
discontinuing oral contraceptives or who do 
not register for prenatal care until late in 
pregnancy. However, those patients who 
can reliably be documented to still be 
pregnant beyond the 42nd week of gestation 
are at an increased risk of progressive 
placental insufficiency78,79 and might be 
expected to have low or falling serum hPL  
values. Such results have been reported.34,54 
However, others have subsequently found 
hPL values to be of little clinical usefulness 
in this situation.80
Several small series81,82 have suggested 
that hPL values may be low in association 
with major fetal congenital anomalies. 
However, in a larger series of 113 preg­
nancies complicated by congenital anom­
alies83 the investigators were unable to 
document any significant difference. Such 
findings might be expected, since low hPL  
values reflect only functional placental 
mass.
The preceding literature review suggests 
that maternal serum hPL values may deviate 
from normal when the pregnancy is com pli­
cated by conditions that dim inish func­
tional placental mass. Low hPL values do 
correlate to some extent with fetal outcome 
in pregnancies complicated by IUGR and 
hypertension. W hile earlier reports sug­
gested that hPL was of value in postmature 
pregnancies, more recent reports have ques­
tioned this recommendation. Elevated hPL  
values in late-second- or early-third-trimes- 
ter pregnancies may be helpful in identify­
ing multiple gestations. Human placental
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lactogen has not been helpful in identifying 
those gestations complicated by fetal anom­
alies. Likewise, hPL values are of little help  
in diabetes or isoimmunization, where the 




Pregnancy-specific betai-glycoprotein (also 
known as Schwangerschaftsspezifisches 
betai-glycoprotein, or SP1) is a glycoprotein 
that can be detected as early as 18-23 days 
after ovulation.84 Although suggestions 
have been made that it is produced in the 
material liver and merely absorbed by the 
trophoblast85 or that it is released from 
disintegrating migrating trophoblastic tis­
sue,86 most authorities agree that it is 
produced by the syncytiotrophoblast.87 Be­
sides being produced by certain tumors, SP1 
is also produced by human fibroblast cell 
strains and human amniotic fluid cell 
cultures.88 Maternal serum levels early in 
pregnancy initially parallel human cho­
rionic gonadotropin (hCG) levels, but SP1 
levels continue to rise beyond 8 weeks of 
pregnancy, suggesting separate synthesis 
sites in the syncytiotrophoblast.89 It has a 
half-life of 30-40 hours.90 The molecular 
weight is 90,000 daltons, and approximately 
30% of the molecule is carbohydrate. On 
electrophoresis it moves as a betarglobulin. 
Like hPL, it has been found to have a larger 
form of molecule.91 It is unclear whether it 
might be a prohormone. However, currently
• • 92available radioimmunoassay techniques 
should minimize this confusion. The smaller 
molecule is now known as the beta-form  and 
was the protein originally described by 
Tatarinov and Masyukevich in 1970.93 The 
larger form is designated the alpha- form .  
Available antisera are reported to vary in 
their ability to recognize SP 1 -alpha, and this 
should always be considered in any clinical 
situation. In addition, Teisner and asso­
ciates91 have also shown that the propor­
tions of SP1-alpha and SPl-beta may vary 
among patients. Although they report that 
the ratio of SP1-alpha to SPl-beta remains 
constant in each patient, Grudzinskas and 
associates94 report that the half-life of SP1- 
alpha is shorter than that of SPl-beta after 
delivery of the placenta. Maternal serum 
levels of SP1 gradually rise through preg­
nancy, in a pattern very similar to the 
secretion of hPL,95 although SP1 levels in 
late pregnancy rise more rapidly than hPL  
levels. This chronologic similarity is also 
paralleled by the placental weight curve. 
SP1 is also present in low concentrations in 
amniotic fluid, maternal urine, and cord 
blood.
The biologic action of SP1 is unclear at 
this time, but it may function in the 
regulation of maternal carbohydrate metab­
olism, as a transport protein, as an im m uno­
suppressive, or with some combination of 
these actions.
Several studies have demonstrated a co­
efficient of variation in late-pregnancy SP1 
values of about 30%.96 While this might sug­
gest a substantial overlap between normal 
and abnormal pregnancies, the intrapatient 
day-to-day variability is remarkably low .97
A multitude of papers in the past 6-7 
years, primarily in the British literature, 
have reported on the usefulness of SP1 in 
m onitoring normal and abnormal preg­
nancy.
SP1 has been reported to be of value in the 
early diagnosis of pregnancy,92 although  
there is no evidence to suggest that it is of 
any more value than currently available 
hCG assays.
First-trimester SP1 values are frequently 
lower in patients who w ill have spon­
taneous first-trimester miscarriages. This 
observation has been applied specifically to 
the problems of threatened abortion98 and 
ectopic pregnancy.99 Chapman and asso­
ciates100 have shown that early-second-tri- 
mester values do not correlate with birth 
weight, placental weight, clinical outcome, 
or AFP values, although others disagree 
with this finding.70,101 However, late-sec­
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ond-trimester and early-third-trimester 
values have been shown to correlate.
Heikinheimo and Unnerus102 have in ­
vestigated the usefulness of SP1 assays in 
preeclamptic pregnancies. Except for those 
preeclamptic pregnancies complicated by 
associated intrauterine growth retardation, 
SP1 values were indistinguishable from 
those of control patients.
Towler and associates have reported that 
high SP1 levels can be of help in the 
diagnosis of multiple gestation.103 Grudzin- 
skas and associates104 have shown SP1 levels 
to be in the normal range in diabetic 
pregnancies.
High SP1 levels have been reported to be 
of use in confirming fetal macrosomia,105 
and low values have reportedly been pre­
dictive of intrauterine growth retarda­
tion,70,106 although not all authors agree 
with the latter finding.107 As with hPL, SP1 
values in maternal serum are lower at any 
duration of pregnancy in women who 
smoke.108
SP1 is produced by trophoblastic tu­
mors109 and has been utilized as a tumor 
marker for patient follow-up.110 It is now 
known to occur in other tumors as well, 
including testicular tumors,105 breast tu­
mors,111 and lung tumors.112
Pregnancy-Associated 
Plasma Protein A
Pregnancy-associated plasma protein A 
(PAPP-A) was isolated from the serum of 
pregnant women by Lin and associates in 
1974.113 The molecule is of placental origin, 
and its concentration increases in parallel 
with the growth of the placenta.95 It is 
produced by the syncytiotrophoblast,87 
although a recent publication suggests that 
PAPP-A may be present in nonpregnant 
sera as well.114 Although not previously 
detected prior to 12 weeks’ gestation, 
recently reported improved immunoassay 
techniques115 allow its reproducible detec­
tion as early as the 6th week of pregnancy.
Smith and associates116 report a steady 
increase in PAPP-A levels throughout the 
third trimester, the highest levels being 
reported in patients in early labor. This is a 
pattern different from that of most of the 
other placental hormones, which tend to 
plateau in the latter weeks of pregnancy. 
Bischof and associates117 have shown that 
increasing maternal age and parity, as well 
as increased maternal body weight, are 
associated with decreased maternal serum 
PAPP-A levels, but that increased maternal 
serum PAPP-A levels were associated with 
pregnancies carrying male fetuses, Rh- 
negative fetuses, and infants with Apgar 
scores higher than 7 at 1 minute. The 
molecular weight of PAPP-A is approxi­
mately 750,000 daltons, and its half-life 
appears to be 3-4 days. Like other placental 
proteins, it is found only in trace con­
centrations in compartments other than the 
maternal circulation.
Bischof has investigated possible biologic 
functions of PAPP-A.118 He demonstrated 
an in vitro inhibition of the complement 
system. In addition, evidence of plasmin 
activation suggested that PAPP-A might 
play a role in the regulation of fibrinolysis 
during pregnancy.
The feasibility of using PAPP-A as a 
screen for pregnancy dysfunction has been 
evaluated. Hughes and associates119 evalu­
ated the test in a series of 272 patients at 34 
weeks’ gestation. They found elevated 
average values in those patients in whom 
preeclampsia, premature labor, or ante­
partum  hemorrhage, were destined to 
develop although there was a wide overlap 
with normal individuals. Patients with 
growth-retarded fetuses w ithout a clinically 




Like PAPP-A, pregnancy-associated plasma 
protein B (PAPP-B) was first identified by
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Lin in 1974.113 It is also a glycoprotein and 
has a molecular weight of approximately 
1,000,000 daltons. Although it moves as a 
betai-globulin on electrophoresis, it is im- 
munochemically unrelated to SP1.95 PAPP- 
B appears in the maternal circulation by the 
early second trimester, increases gradually 
thereafter until term, has a half-life of less 
than 24 hours, and has not been detected in 
either amniotic fluid or cord blood.
Very little information is currently avail­
able regarding clinical correlation with 
PAPP-B levels. Lin, Halbert, and Spellacy120 
found that PAPP-B levels in maternal 
circulation correlated with placental weight 
but did not correlate with maternal size, 
parity, age, blood pressure, or fetal weight. 
They did find that maternal PAPP-B levels 
were decreased in preeclampsia and dia­
betes. It appeared that PAPP-B levels might 
be increased with m ultiple gestation, a l­
though only a very small number of cases 
were studied.
Placental Proteins
In 1972, Bohn reported the isolation of a 
number of proteins in hum an placenta 
extracts.121 These substances have since been 
named placental proteins (PP) and have 
been classified by the arbitrary assignment 
of consecutive numbers 1 through 7. Only 
two have received significant evaluation: 
PP2 has been found to be ferritin, and PP5 
has been evaluated in an assay of placental 
function.
PP1 is an alphai-glycoprotein with a 
molecular weight of approximately 160,000. 
It has been localized to both villous stroma 
and syncytiotrophoblasts but is not specific 
for either the placenta or pregnancy.122
PP3 and PP4 have not been well charac­
terized but do not appear to be specific for 
the placenta.123
PP6 is also an alphai-glycoprotein that 
can be found in the nuclei of syncytiotro- 
phoblastic cells.124 However, it is not spe­
cific for the placenta.125
PP7 is also a glycoprotein that can be 
isolated from the placenta but not from the 
serum of pregnant women.126
Placental Protein 5
Placental protein 5 (PP5) is a glycoprotein 
that contains 20% carbohydrate, moves as a 
betai-globulin on electrophoresis, and has a 
molecular weight of 36,000 daltons.127 U n­
like many of the other placental hormones, 
PP5 can be localized in the stroma of the 
placental villi as well as in the syncytiotro- 
phoblast,124 suggesting that although PP5 
appears in the maternal circulation, it is 
really a tissue protein. This theory would be 
compatible with the observations that ma­
ternal circulating levels of PP5, even at term, 
128are very low. Maternal serum values 
increase approximately tenfold from 8-10 
weeks to 37 weeks, after which time they 
remain constant or decrease slightly.129 Post­
partum  clearance from maternal serum 
follows a biphasic pattern, with an initial 
rapid decrease in values over the first 
postpartum hour, followed by a subsequent 
slow decrease over the next 6-7 days.129
Because maternal serum concentrations of 
PP5 are very low in the first trimester of 
normal pregnancies, it is unlikely that PP5 
levels will be of value in the management of 
first-trimester complications of pregnancy. 
Salem and associates have shown a relation­
ship between high midtrimester maternal 
serum PP5 levels and subsequent premature 
delivery.101 Nesbit and associates have also 
recently reported on PP5 levels in compli­
cated pregnancies.130 PP5 levels in preg­
nancies involving intrauterine growth retar­
dation were indistinguishable from control 
patient values. Patients with preeclampsia 
and multiple gestation have higher PP5 
values than control patients, but a wide 
overlap exists. Interestingly, diabetic preg­
nancy was characterized by low maternal 
serum PP5 values in the first and second 
trimesters, but high levels in the third 
trimester. The clinical applicability of such 
results is unclear at this time.
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PP5 values are elevated in patients who 
subsequently have placental abruption.131 
This may in part explain the increased 
tendency toward consumptive coagulo­
pathy in these patients, because Bohn and 
Winckler127 have previously shown that PP5 
is an inhibitor of trypsin and plasmin. 
Salem and associates have also shown that 
addition of protamine to pregnancy serum 
causes an increase in levels of PP5,132 this 
finding being less common in diabetic and 
preeclamptic pregnancies than in normal 
subjects. They suggest that this provides 
further evidence that PP5 maybe involved in 
the coagulation system, in particular in 
abnormal coagulation processes at the 
placental site.
PP5 has also been found in patients with 
trophoblastic tumors and certain non- 
trophoblastic malignancies, including tera­
tomas and breast tumors.
Pregnancy-Associated 
Alp ha 2-Gly coprotein
Pregnancy-associated alpha 2-glycoprotein 
(Q2-PAG) is a high-molecular-weight glyco­
protein present in pregnancy serum in large 
amounts. However, it is also present in 
normal male and nonpregnant female sera, 
being higher in females than in males and 
increasing with age.105 Maternal steroid 
administration diminishes a 2-PAG levels by 
more than 50%.133 This finding may be of 
significance in high-risk pregnancies treated 
with steroids to accelerate fetal pulmonary
* •„ 134,135maturity.
During pregnancy Q2-PAG levels progres­
sively rise until about 34 weeks,136 then 
remain constant or may fall slightly. The 
half-life of a 2 -PAG, as judged by its 
disappearance rate postpartum, is probably 
6-7 days.
The exact site of a 2-PAG synthesis is 
unclear, but it is probably the result of 
estrogen-mediated leukocyte stim ulation.137 
It is not produced by the trophoblast. Both 
because of this latter fact and because of a
variable distribution of levels, a 2-PAG has 
not generally been useful in monitoring 
fetal-placental function.
Damber and associates137 have shown that 
women who have spontaneous abortions 
have lower a 2-PAG levels than do normals, 
although the degree of overlap is sub­
stantial.
Disagreement currently exists as to 
whether a 2-PAG appears to be of marginal 
value as a tumor marker.138-140
Conclusion
The past few years have seen a progressive 
decrease in clinical indications for maternal 
serum hPL determinations. Many insti­
tutions no longer employ hPL assays in 
their fetal surveillance protocols. Although 
less experience has been accumulated with 
the other pregnancy-associated hormones 
covered in this review, many authors— 
especially those from England and Scot­
land—are currently quite enthusiastic about 
their clinical applicability. Such enthu­
siasm is reminiscent of that encountered 
with maternal serum hPL determinations 
during the preceding decade, and it remains 
to be seen whether these newer pregnancy- 
associated hormone assays will pass into 
similar disfavor. These newer hormones 
have raised several fascinating questions. 
For example, does PAPP-A really increase 
more rapidly in those patients destined to 
become preeclamptic? Does PP5 really 
increase more rapidly in patients destined 
for placental abruption? Is the true function 
of these substances related to im m uno­
suppression? If so, m ight they hold clues for 
immunosuppression in nonobstetric areas? 
Or might they be of value as antigens for 
immunologic sterilization?
Although such clinically oriented ques­
tions are intriguing, a reproducible trend 
seems obvious as a result of the preparation 
of this review, namely, that new discoveries 
are easy prey for immediate clinical 
correlation studies. While such correlations
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may be of considerable value in providing 
optimal care for our patients, it is only with 
further understanding of the basic phys­
iologic functions of these substances that we 
will be able to interpret them in a truly 
knowledgeable fashion.
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